Cargando…
Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2
SARS-CoV-2 Omicron BA.2.75 has diversified into multiple subvariants with additional spike mutations and several are expanding in prevalence, particularly CH.1.1 and BN.1. Here, we investigated the viral receptor affinities and neutralization evasion properties of major BA.2.75 subvariants actively...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654603/ https://www.ncbi.nlm.nih.gov/pubmed/38026207 http://dx.doi.org/10.1016/j.isci.2023.108254 |
_version_ | 1785136660524040192 |
---|---|
author | Wang, Qian Li, Zhiteng Guo, Yicheng Mellis, Ian A. Iketani, Sho Liu, Michael Yu, Jian Valdez, Riccardo Lauring, Adam S. Sheng, Zizhang Gordon, Aubree Liu, Lihong Ho, David D. |
author_facet | Wang, Qian Li, Zhiteng Guo, Yicheng Mellis, Ian A. Iketani, Sho Liu, Michael Yu, Jian Valdez, Riccardo Lauring, Adam S. Sheng, Zizhang Gordon, Aubree Liu, Lihong Ho, David D. |
author_sort | Wang, Qian |
collection | PubMed |
description | SARS-CoV-2 Omicron BA.2.75 has diversified into multiple subvariants with additional spike mutations and several are expanding in prevalence, particularly CH.1.1 and BN.1. Here, we investigated the viral receptor affinities and neutralization evasion properties of major BA.2.75 subvariants actively circulating in different regions worldwide. We found two distinct evolutionary pathways and three newly identified mutations that shaped the virological features of these subvariants. One phenotypic group exhibited a discernible decrease in viral receptor affinities, but a noteworthy increase in resistance to antibody neutralization, as exemplified by CH.1.1, which is apparently as resistant as XBB.1.5. In contrast, a second group demonstrated a substantial increase in viral receptor affinity but only a moderate increase in antibody evasion, as exemplified by BN.1. We also observed that all prevalent SARS-CoV-2 variants in the circulation presently, except for BN.1, exhibit profound levels of antibody evasion, suggesting this is the dominant determinant of virus transmissibility today. |
format | Online Article Text |
id | pubmed-10654603 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-106546032023-10-18 Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2 Wang, Qian Li, Zhiteng Guo, Yicheng Mellis, Ian A. Iketani, Sho Liu, Michael Yu, Jian Valdez, Riccardo Lauring, Adam S. Sheng, Zizhang Gordon, Aubree Liu, Lihong Ho, David D. iScience Article SARS-CoV-2 Omicron BA.2.75 has diversified into multiple subvariants with additional spike mutations and several are expanding in prevalence, particularly CH.1.1 and BN.1. Here, we investigated the viral receptor affinities and neutralization evasion properties of major BA.2.75 subvariants actively circulating in different regions worldwide. We found two distinct evolutionary pathways and three newly identified mutations that shaped the virological features of these subvariants. One phenotypic group exhibited a discernible decrease in viral receptor affinities, but a noteworthy increase in resistance to antibody neutralization, as exemplified by CH.1.1, which is apparently as resistant as XBB.1.5. In contrast, a second group demonstrated a substantial increase in viral receptor affinity but only a moderate increase in antibody evasion, as exemplified by BN.1. We also observed that all prevalent SARS-CoV-2 variants in the circulation presently, except for BN.1, exhibit profound levels of antibody evasion, suggesting this is the dominant determinant of virus transmissibility today. Elsevier 2023-10-18 /pmc/articles/PMC10654603/ /pubmed/38026207 http://dx.doi.org/10.1016/j.isci.2023.108254 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wang, Qian Li, Zhiteng Guo, Yicheng Mellis, Ian A. Iketani, Sho Liu, Michael Yu, Jian Valdez, Riccardo Lauring, Adam S. Sheng, Zizhang Gordon, Aubree Liu, Lihong Ho, David D. Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2 |
title | Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2 |
title_full | Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2 |
title_fullStr | Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2 |
title_full_unstemmed | Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2 |
title_short | Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2 |
title_sort | evolving antibody evasion and receptor affinity of the omicron ba.2.75 sublineage of sars-cov-2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654603/ https://www.ncbi.nlm.nih.gov/pubmed/38026207 http://dx.doi.org/10.1016/j.isci.2023.108254 |
work_keys_str_mv | AT wangqian evolvingantibodyevasionandreceptoraffinityoftheomicronba275sublineageofsarscov2 AT lizhiteng evolvingantibodyevasionandreceptoraffinityoftheomicronba275sublineageofsarscov2 AT guoyicheng evolvingantibodyevasionandreceptoraffinityoftheomicronba275sublineageofsarscov2 AT mellisiana evolvingantibodyevasionandreceptoraffinityoftheomicronba275sublineageofsarscov2 AT iketanisho evolvingantibodyevasionandreceptoraffinityoftheomicronba275sublineageofsarscov2 AT liumichael evolvingantibodyevasionandreceptoraffinityoftheomicronba275sublineageofsarscov2 AT yujian evolvingantibodyevasionandreceptoraffinityoftheomicronba275sublineageofsarscov2 AT valdezriccardo evolvingantibodyevasionandreceptoraffinityoftheomicronba275sublineageofsarscov2 AT lauringadams evolvingantibodyevasionandreceptoraffinityoftheomicronba275sublineageofsarscov2 AT shengzizhang evolvingantibodyevasionandreceptoraffinityoftheomicronba275sublineageofsarscov2 AT gordonaubree evolvingantibodyevasionandreceptoraffinityoftheomicronba275sublineageofsarscov2 AT liulihong evolvingantibodyevasionandreceptoraffinityoftheomicronba275sublineageofsarscov2 AT hodavidd evolvingantibodyevasionandreceptoraffinityoftheomicronba275sublineageofsarscov2 |